Worth reading
58In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Improvement
Direction inferred from the company’s description.Scale
12.1
Revenue year-on-year (%)Wording
Definitive
How definitive the wording is.Contents of this document
Supplementary materials to the earnings reportSecond quarter (interim period) of the fiscal year ending March 20279 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥57,639 million+12.1%
Operating profit¥6,890 million+14.5%
Ordinary income¥7,142 million+14.2%
Net income¥4,726 million+9.2%
Gross Profit Margin30.5 %
Operating profit margin12 %
Selling, general and administrative expenses¥10,717 million
Results for the three months of the current quarter
Net Sales
¥27,637 million+7.2%
Laboratory Revenue
¥17,049 million+6.9%
Industry revenue
¥6,234 million+8.3%
Medical revenue
¥4,208 million+7.3%
Full-year earnings forecast
Net Sales
¥120,870 million
Gross profit
¥36,610 million
Operating profit
¥13,750 million
Ordinary income
¥14,150 million
Profit attributable to owners of the parent
¥9,500 million
Annual dividend
¥69 /share
What the company explained in this material
Self-assessment against the planThe company's self-assessment against its own plan.
Selling, general and administrative expenses are expected to remain broadly in line with the initial plan.Breakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
- Increase in the number of lines¥1,530 million
- Increase in the average price per line¥270 million
- Increase in the mix of original products¥70 million
- Change in gross margin¥-80 million
- Affiliates and other¥80 million
Assumptions Underlying the Business OutlookThe assumptions used by the company in preparing its forecast.
- Medical fee revision3.09 % increase
- Priority investment areas17 Sector
New initiatives
- New search engine AXEL2.0
- Integration of SmartDC and Tokyo DC
- Establishment and relocation of the Rental & Calibration Center
- Expansion of the rollout of the ocean centralized procurement system
Key KPIsA metric the company considers important as a management benchmark.
- Total e-commerce sales¥21,552 millionYear on year against the same period last year+23.0%
- Product Range1,483 10,000 productsYear on year against the same period last year+12.7%
- Sales of products listed exclusively online¥12,981 millionYear on year against the same period last year+29.1%
- Service revenue¥1,906 millionYear on year against the same period last year+7.0%
- Original-product sales¥19,072 millionYear on year against the same period last year+14.4%
- Overseas Sales¥3,564 millionYear on year against the same period last year+18.0%
- Transaction value processed through the Triumph21 purchasing agency system¥170 100 millionYear on year against the same period last year+9.3%
Segment results
- LaboratoryNet Sales¥35,660 millionYear on year against the same period last year+12.1%
- IndustryNet Sales¥12,930 millionYear on year against the same period last year+13.3%
- MedicalNet Sales¥8,751 millionYear on year against the same period last year+10.8%
Risk amount incorporated into the outlookThe amount representing the range of variation the company expects in its forecast.
¥247 million
DetailsExtraordinary loss associated with the demolition of the old Rental & Calibration Center building and the consolidation of logistics bases in the Kanto region
Number of employees
Number of Employees
48 People
NotesIncrease in headcount from the end of the prior-year second quarter
Hiring planMid-career hiring has been accelerated since the second half of the prior fiscal year
Annual Dividend
¥69 /share
| Item | Details |
|---|---|
| Document type | Supplementary materials to the earnings report |
| Fiscal Period Covered | Second quarter (interim period) of the fiscal year ending March 2027 |
| Net Sales | ¥57,639 million (YoY +12.1%) |
| Operating profit | ¥6,890 million (YoY +14.5%) |
| Ordinary income | ¥7,142 million (YoY +14.2%) |
| Net income | ¥4,726 million (YoY +9.2%) |
| Gross Profit Margin | 30.5 % |
| Operating profit margin | 12 % |
| Selling, general and administrative expenses | ¥10,717 million |
| Results for the three months of the current quarter | Net Sales ¥27,637 million (YoY +7.2%) / Laboratory Revenue ¥17,049 million (YoY +6.9%) / Industry revenue ¥6,234 million (YoY +8.3%) / Medical revenue ¥4,208 million (YoY +7.3%) |
| Full-year earnings forecast | Net Sales ¥120,870 million / Gross profit ¥36,610 million / Operating profit ¥13,750 million / Ordinary income ¥14,150 million / Profit attributable to owners of the parent ¥9,500 million / Annual dividend ¥69 /share |
| Self-assessment against the plan | Selling, general and administrative expenses are expected to remain broadly in line with the initial plan. |
| Segment results | Segment Laboratory / Net Sales ¥35,660 million / Year on year against the same period last year 12.1, Segment Industry / Net Sales ¥12,930 million / Year on year against the same period last year 13.3, Segment Medical / Net Sales ¥8,751 million / Year on year against the same period last year 10.8 |
| Breakdown of Factors Affecting the Change | Factors Increase in the number of lines / Amount ¥1,530 million, Factors Increase in the average price per line / Amount ¥270 million, Factors Increase in the mix of original products / Amount ¥70 million, Factors Change in gross margin / Amount ¥-80 million, Factors Affiliates and other / Amount ¥80 million |
| Key KPIs | Total e-commerce sales ¥21,552 million, Product Range 1,483 10,000 products, Sales of products listed exclusively online ¥12,981 million, Service revenue ¥1,906 million, Original-product sales ¥19,072 million, Overseas Sales ¥3,564 million, Transaction value processed through the Triumph21 purchasing agency system ¥170 100 million |
| Number of employees | Number of Employees 48 People / Hiring plan Mid-career hiring has been accelerated since the second half of the prior fiscal year |
| Assumptions Underlying the Business Outlook | Medical fee revision 3.09 % increase, Priority investment areas 17 Sector |
| Risk amount incorporated into the outlook | ¥247 million |
| Annual Dividend | ¥69 /share |
| New initiatives | New search engine AXEL2.0, Integration of SmartDC and Tokyo DC, Establishment and relocation of the Rental & Calibration Center, Expansion of the rollout of the ocean centralized procurement system |
Items this document does not state (11)
Progress against full-year forecastUnit price and quantity metricsNumber of stores and locationsMedium-term management plan targetsFinancial targetsPayout ratioAcquisition of treasury sharesCapital expendituresOrders received and order backlogMarket Size / ShareKey points of the Q&A
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Sales increased across the various sectors, driven by corporate research and development spending, demand related to AI and government support measures. Sales through the centralized procurement system "ocean" and e-commerce sales also grew. Increased demand for certain products due to the situation in the Middle East, growth in sales of original products and agile price updates also contributed.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.